ClinicalTrials.gov
ClinicalTrials.gov Menu

Gait Speed for Predicting Cardiovascular Events After Myocardial Infarction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01484158
Recruitment Status : Completed
First Posted : December 2, 2011
Last Update Posted : January 22, 2015
Sponsor:
Information provided by (Responsible Party):
Yasushi Matsuzawa, Yokohama City University Medical Center

Brief Summary:
There are growing evidences that gait speed is inversely associated with all causes mortality especially cardiovascular mortality among the elderly. The purpose of this study is to evaluate the predictive value of gait speed for cardiovascular events in patients after ST-segment elevation myocardial infarction (STEMI).

Condition or disease
Myocardial Infarction

Detailed Description:
The investigators will enroll patients capable of walking with STEMI. All patients will receive successful reperfusion therapy within 12-hour from onset. Gait speed during cardiac rehabilitation is measured. Cardiovascular events were defined as a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, for an average follow-up period.

Study Type : Observational
Actual Enrollment : 450 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Gait Speed for Predicting Cardiovascular Events After Myocardial Infarction
Study Start Date : October 2001
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack
U.S. FDA Resources

Group/Cohort
Myocardial Infarction
Patients with myocardial infarction



Primary Outcome Measures :
  1. Cardiovascular Events [ Time Frame: 5 years ]
    cardiovascular death, non-fatal myocardial infarction and non-fatal stroke


Biospecimen Retention:   Samples Without DNA
We retain only blood sample only in this study.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with acute myocardial infarction.
Criteria

Inclusion Criteria:

  • Clinical diagnosis of ST-segment elevation acute myocardial infarction
  • Must be treated within 12 hours after symptom onset
  • Must be able to walk
  • Must receive successful primary percutaneous coronary intervention

Exclusion Criteria:

  • History of prior myocardial infarction
  • Cerebrovascular disease with residual hemiplegia
  • Severe peripheral arterial disease

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Yasushi Matsuzawa, Primary Investigator, Yokohama City University Medical Center
ClinicalTrials.gov Identifier: NCT01484158     History of Changes
Other Study ID Numbers: Gait Speed Outcome Study
First Posted: December 2, 2011    Key Record Dates
Last Update Posted: January 22, 2015
Last Verified: January 2015

Keywords provided by Yasushi Matsuzawa, Yokohama City University Medical Center:
Myocardial Infarction

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases